1. Home
  2. MSEX vs GERN Comparison

MSEX vs GERN Comparison

Compare MSEX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Middlesex Water Company

MSEX

Middlesex Water Company

HOLD

Current Price

$52.28

Market Cap

998.7M

Sector

Utilities

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.39

Market Cap

900.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSEX
GERN
Founded
1897
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
998.7M
900.1M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
MSEX
GERN
Price
$52.28
$1.39
Analyst Decision
Buy
Buy
Analyst Count
3
7
Target Price
$60.33
$3.00
AVG Volume (30 Days)
100.1K
9.1M
Earning Date
02-27-2026
02-25-2026
Dividend Yield
2.75%
N/A
EPS Growth
3.71
N/A
EPS
2.39
N/A
Revenue
$194,822,000.00
$183,403,000.00
Revenue This Year
$4.02
$147.42
Revenue Next Year
$8.35
$37.07
P/E Ratio
$21.92
N/A
Revenue Growth
6.24
522.13
52 Week Low
$44.17
$1.04
52 Week High
$67.09
$3.12

Technical Indicators

Market Signals
Indicator
MSEX
GERN
Relative Strength Index (RSI) 48.97 54.24
Support Level $52.85 $1.26
Resistance Level $53.98 $1.37
Average True Range (ATR) 1.24 0.08
MACD 0.13 -0.00
Stochastic Oscillator 44.92 52.27

Price Performance

Historical Comparison
MSEX
GERN

About MSEX Middlesex Water Company

Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: